Volume 95 Issue 30 | pp. 24-25 | C&EN Talks With
Issue Date: July 24, 2017 | Web Date: July 18, 2017

Los Alamos scientist explores the outer reaches of the periodic table

Stosh Kozimor discusses his work with actinides and how these radioactive elements might help treat cancer
By Mark Peplow, special to C&EN
Department: Science & Technology
Keywords: radiochemistry, actinides, Stosh Kozimor, actinium, ligands, covalency, cancer
[+]Enlarge

Kozimor

Credit: Josh Smith/Los Alamos National Laboratory
A photo of Stosh Kozimor of Los Alamos National Laboratory.
 

Kozimor

Credit: Josh Smith/Los Alamos National Laboratory
Vitals

Studies: B.Sc., Fort Lewis College, 1999; Ph.D., University of California, Irvine, 2005

Best part of his job: Mentoring. I am inspired by the hard-working and creative people at Los Alamos National Laboratory, and the students are especially fun.

Favorite molecule: I am fascinated by the actinium-oxygen interactions in actinyl compounds, and I love huge multimetallic clusters. But my favorite compounds are those we haven’t made yet. For example, Nikolas Kaltsoyannis at the University of Manchester recently published a calculation on AcHe173+ (Angew. Chem. Int. Ed. 2017, DOI: 10.1002/anie.201700245). Imagine making that molecule.

Hobbies: I like sneaking off with my kids to get a free scoop of ice cream at the local grocery store and grilling in the backyard while I watch the boys run through the park. I love everything outdoors with my family.

If the periodic table is an atlas for chemistry, then the actinides should surely be labeled “Here be dragons.” All are radioactive, only thorium and uranium are found in appreciable quantities, and most of the rest are produced by the sort of modern-day alchemy that relies on nuclear reactors or particle accelerators.

Stosh Kozimor, a staff scientist at Los Alamos National Laboratory, is one of a hardy band of scientists unafraid of taming these dragons. Mark Peplow spoke with him about the challenges of doing research on the actinides and their potential application in cancer therapy.

What attracted you to studying the actinides?

I grew up in New Mexico, and with Los Alamos being so close, there was always talk about the Cold War, nuclear power, and the Manhattan Project. I was turned off, I guess, by that. But there was also an allure to it. I was curious about the problems and the issues, and I just kept coming back to it.

How difficult is it to work with actinides?

When you have highly radioactive samples, you want to limit your personal exposure to them, and the material is usually very scarce and incredibly valuable. So there’s a lot of up-front work using nonradioactive surrogates to make sure the entire process is well rehearsed and your hands develop muscle memory. It takes an incredible amount of mental focus just to load a cuvette because you don’t want anything to splatter.

A lot of times we’ll work in pairs to carry out a delicate manipulation, so you need a second person whom you can get along with and who wants to work on that project with you. You have to have a healthy respect for the material. If it doesn’t make you anxious, you probably shouldn’t be handling it.

What’s the goal of your research?

We’re interested in understanding how covalent or ionic the bonds are between actinides and ligands and how that changes along the actinide series. It’s one of the most fundamental questions in actinide science. It’s important for a lot of reasons: Covalency is invoked in explaining the fate and transport of actinides in the environment—how they behave in water or soil, for example—in trying to build good ligands for them, and in separating them from each other.

Aside from fundamental studies, are you looking into novel applications for actinides?

Isotopes that emit α particles have the potential to treat cancers. You have to attach the radioisotope to a chelator, a molecule that binds the actinide and holds onto it in someone’s body. Then you attach that to a biological targeting vector that takes it to the tumor. Actinide isotopes such as actinium-225, thorium-227, and uranium-230 are short-lived, so they’re not a long-term toxic threat, and α particles only penetrate a short distance into biological tissue, so there could be fewer side effects than nontargeted treatments.

Actinium-225 has a 10-day half-life. It decays to give off an α particle, and then its decay products subsequently produce three more α particles. That’s four α particles for every actinium atom, so you get a lot of bang for your buck.

We’re trying to develop better chelators for holding on to actinium as we put it in the body. As a baseline, we needed to characterize how actinium coordinates to water molecules, even though other ligands may be more important for controlling the fate and transport of actinium in the body.

We made the first bond distance measurements for actinium coordination complexes (Nat. Commun. 2016, DOI: 10.1038/ncomms12312), and it’s surprising how long those distances are in the actinium-water complex: an average of 2.63 Å. The coordination number was also higher than expected, with 10.9 ± 0.5 water molecules in each actinium’s inner coordination sphere (ACS Cent. Sci. 2017, DOI: 10.1021/acscentsci.6b00356). The error bar on our measurement is quite high, but the general trend is that it’s going to take a relatively large ligand to cover all those coordination sites, which is what you need to chelate actinium effectively in the body.

Researchers already have little chelators that are good at binding small lanthanides such as gadolinium, but there’s no possible way they’re the right size for actinium—actinium is the largest +3 oxidation-state metal on the periodic table. So our main focus now is to design and build macrocycle compounds, which are larger, to reach around and hug it tighter. We’re hoping to get some initial results out soon.


Mark Peplow is a freelance writer. A version of this story first appeared in ACS Central Science: cenm.ag/kozimor. This interview was edited for length and clarity.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society
Comments
david chettle (Wed Jul 19 21:22:11 EDT 2017)
They tell me I have atypical parkinson's. I have heard that Al from our saucepans my be involved. Do you know anything about this. Keep up the good work. You fellows amaze me.
Bill (Wed Jul 19 22:30:45 EDT 2017)
Aluminum is indeed implicated in Parkinson's. Bear in mind that aluminum is in every food you eat, as it's in all soils, but there is likely a difference between metallic aluminum and the aluminum compounds in common soil. You may want to look into spirulina algae, as it has been used to detox the body from heavy metals, and even radiation. You may also want to take advantage of the 8 doctors - clean water (distilled is best, RO a distant second), clean air, exercise (a 20 minute brisk walk, twice a day), sunshine, clean food (a vegan diet is best, at least for now; fruit, by itself, and vegetables, grains and nuts; absolutely no sugar except for what is in fruit, no alcohol, no coffee, no drugs, ie.e, temperance), rest (at least 7 hours uninterrupted sleep per night), and trust in God. If you bring about the proper conditions for healing to take place, it will happen. Good luck, hope you get better.
R. E. Buntrock (Thu Jul 20 16:00:25 EDT 2017)
Please cite valid relevant references to the implication of AL in Parkinson's. Note that metallic/elemental Al will not be extracted from Al in cooking utensils. Metallic aluminum is so reactive that it forms a transparent adherent coating of aluminum oxide. Any further extraction would be of Al compounds, not metallic aluminum. Finally, Al is not a heavy metal. Per another commenter, the religious reference may contribute to the mental state of the patient but other than that hopefully calming effect, it will probably have no effect on the physical condition.
J-F Gal (Thu Jul 20 02:25:44 EDT 2017)
Is it the place to tell about God (which one?) and diets by non-chemists?
R. E. Buntrock (Thu Jul 20 15:52:34 EDT 2017)
Am I the only one who doesn't see the relevance of the first two comments to the article?
Leave A Comment